A look at the shareholders of Pfizer Inc. (NYSE:PFE) can tell us which group is most powerful. The group holding the most ...

Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over the past decade.

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 95% based on the firm’s underlying fundamentals and the stock’s valuation.

Pfizer yields 5.57% with a B- dividend safety rating, known for Eliquis and Xeljanz. Find out why I'm bullish on PFE stock.

This was the stock's third consecutive day of losses.

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Starboard Value engages with Pfizer's leadership amid growing concerns over the company's trajectory. Meanwhile, Pfizer reports a significant survival benefit in prostate cancer patients from its ...